Epigenomics Aktie
| 0,88EUR | -0,40EUR | -31,25% |
WKN DE: A37FT4 / ISIN: DE000A37FT41
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 37 | 32 | 34 | 0 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,02 | 0,19 | 0,01 | 0,00 | 0,00 |
Bilanz (in Mio. EUR) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 5 | 24 | 11 | 2 | 1 |
| Summe Anlagevermögen | 1 | 1 | 5 | 2 | 0 |
| Summe Aktiva | 7 | 25 | 16 | 5 | 1 |
Bilanz (in Mio. EUR) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 3 | 3 | 6 | 13 | 12 |
| Summe Eigenkapital | 4 | 22 | 10 | -8 | -11 |
| Summe Passiva | 7 | 25 | 16 | 5 | 1 |
Adresse
| Ziegelhäuser Landstrasse 3, 69120 Heidelberg | |
| Telefon | +49 (62) 2164-924-87 |
| Internet | http://www.epigenomics.com/de/ |
Management
|
Alexander Link
Deputy Chairman-Supervisory Board |
|
Annett Dietrich
Manager-Human Resources |
|
Frederic Hilke
Head-Media & Investor Relations Contact |
|
Hansjörg Plaggemars
Member-Management Board |
|
Hansjörg Plaggemars
Director |
|
Helge Lubenow
Chairman-Supervisory Board |
|
Jochen Hummel
Independent Member-Supervisory Board |